The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved China-based Hansoh Pharmaceutical Group Co., Ltd.’s (HKG: 3692) almonertinib, marketed as Aumseqa, for the treatment of non-small cell lung cancer (NSCLC). The approval specifically covers patients with epidermal growth factor receptor (EGFR) mutations who have not yet received treatment for metastatic disease.
Clinical Trial Results
Almonertinib, a third-generation EGFR-TKI, demonstrated significant efficacy in a Phase 3 clinical trial. It reduced the risk of disease progression or death by 54% in patients with advanced or metastatic NSCLC with specific EGFR mutations, compared to gefitinib.-Fineline Info & Tech
